These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 37553080)

  • 41. Novel antidiabetic drugs and risk of cardiovascular events in patients without baseline metformin use: a meta-analysis.
    Masson W; Lavalle-Cobo A; Lobo M; Masson G; Molinero G
    Eur J Prev Cardiol; 2021 Mar; 28(1):69-75. PubMed ID: 33606884
    [TBL] [Abstract][Full Text] [Related]  

  • 42. GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off.
    Giugliano D; Scappaticcio L; Longo M; Bellastella G; Esposito K
    Cardiovasc Diabetol; 2021 Oct; 20(1):205. PubMed ID: 34641876
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Positioning sulphonylureas in a modern treatment algorithm for patients with type 2 diabetes: Expert opinion from a European consensus panel.
    Consoli A; Czupryniak L; Duarte R; Jermendy G; Kautzky-Willer A; Mathieu C; Melo M; Mosenzon O; Nobels F; Papanas N; Roman G; Schnell O; Sotiropoulos A; Stehouwer CDA; Tack CJ; Woo V; Fadini GP; Raz I
    Diabetes Obes Metab; 2020 Oct; 22(10):1705-1713. PubMed ID: 32476244
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Use of sodium-glucose co-transporter-2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure.
    Butler J; Handelsman Y; Bakris G; Verma S
    Eur J Heart Fail; 2020 Apr; 22(4):604-617. PubMed ID: 31926059
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Adoption of sodium-glucose cotransporter-2 inhibitors among prescribers caring for nursing home residents.
    Hayes KN; Berry SD; Munshi MN; Zullo AR
    J Am Geriatr Soc; 2023 Aug; 71(8):2585-2592. PubMed ID: 37078149
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Do GLP-1RAs and SGLT-2is reduce cardiovascular events in women with type 2 diabetes? A systematic review and meta-analysis.
    Mishriky BM; Okunrintemi V; Jain S; Sewell KA; Powell JR; Cummings DM
    Diabetes Metab; 2021 Feb; 47(1):101160. PubMed ID: 32439471
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prescribing sodium-glucose co-transporter-2 inhibitors for type 2 diabetes in primary care: influence of renal function and heart failure diagnosis.
    Hinton W; Feher MD; Munro N; Joy M; de Lusignan S
    Cardiovasc Diabetol; 2021 Jun; 20(1):130. PubMed ID: 34183018
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparative safety of dipeptidyl peptidase-4 inhibitors and sulfonylureas among frail older adults.
    Zullo AR; Smith RJ; Gutman R; Kohler B; Duprey MS; Berry SD; Munshi MN; Dore DD
    J Am Geriatr Soc; 2021 Oct; 69(10):2923-2930. PubMed ID: 34291453
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Improving heart failure outcomes with sodium-glucose cotransporter 2 inhibitors in different patient groups.
    Jhund PS
    Diabetes Obes Metab; 2023 Jul; 25 Suppl 3(Suppl 3):26-32. PubMed ID: 37334518
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Telehealth Intervention to Improve Uptake of Evidence-Based Medications among Patients with Type 2 Diabetes and Heart Failure or Cardiovascular Disease.
    Silva-Almodóvar A; Nahata MC
    Int J Environ Res Public Health; 2023 Feb; 20(4):. PubMed ID: 36834307
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
    Handelsman Y
    Adv Ther; 2019 Oct; 36(10):2567-2586. PubMed ID: 31444707
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sodium-Glucose Cotransport Protein 2 Inhibitors in Patients With Type 2 Diabetes and Acute Kidney Disease.
    Pan HC; Chen JY; Chen HY; Yeh FY; Huang TT; Sun CY; Wang SI; Wei JC; Wu VC
    JAMA Netw Open; 2024 Jan; 7(1):e2350050. PubMed ID: 38170522
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors Versus Metformin : A Cohort Study.
    Shin H; Schneeweiss S; Glynn RJ; Patorno E
    Ann Intern Med; 2022 Jul; 175(7):927-937. PubMed ID: 35605236
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A real-world data analysis.
    Colosimo S; Ravaioli F; Petroni ML; Brodosi L; Marchignoli F; Barbanti FA; Sasdelli AS; Marchesini G; Pironi L
    Liver Int; 2021 Apr; 41(4):731-742. PubMed ID: 33497019
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacologic strategies to reduce cardiovascular disease in type 2 diabetes mellitus: focus on SGLT-2 inhibitors and GLP-1 receptor agonists.
    Bonaventura A; Carbone S; Dixon DL; Abbate A; Montecucco F
    J Intern Med; 2019 Jul; 286(1):16-31. PubMed ID: 30888088
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors vs. Dipeptidyl Peptidase-4 Inhibitors in Frail People With Diabetes Who Were Recently Hospitalized.
    Wood SJ; Bell JS; Magliano DJ; Shaw JE; Cesari M; Ilomaki J
    Front Pharmacol; 2022; 13():886834. PubMed ID: 35903329
    [No Abstract]   [Full Text] [Related]  

  • 57. The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes.
    Woo V; Connelly K; Lin P; McFarlane P
    Curr Med Res Opin; 2019 Jul; 35(7):1283-1295. PubMed ID: 30767677
    [No Abstract]   [Full Text] [Related]  

  • 58. Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study.
    Baviera M; Foresta A; Colacioppo P; Macaluso G; Roncaglioni MC; Tettamanti M; Fortino I; Genovese S; Caruso I; Giorgino F
    Cardiovasc Diabetol; 2022 Aug; 21(1):162. PubMed ID: 35999556
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence.
    Natali A; Nesti L; Tricò D; Ferrannini E
    Cardiovasc Diabetol; 2021 Sep; 20(1):196. PubMed ID: 34583699
    [TBL] [Abstract][Full Text] [Related]  

  • 60. New Antipsychotic Prescribing Continued into Skilled Nursing Facilities Following a Heart Failure Hospitalization: a Retrospective Cohort Study.
    Riester MR; Goyal P; Jiang L; Erqou S; Rudolph JL; McGeary JE; Rogus-Pulia NM; Madrigal C; Quach L; Wu WC; Zullo AR
    J Gen Intern Med; 2022 Oct; 37(13):3368-3379. PubMed ID: 34981366
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.